Patents by Inventor Kenji Matsuno
Kenji Matsuno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7329655Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomeruloscierosis.Type: GrantFiled: August 17, 2001Date of Patent: February 12, 2008Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Patent number: 7265486Abstract: In an LED (Light Emitting Diode) including a cover covering an LED element, the cover is formed using glass having a composition RnSiO2-n/2. The glass according to the present invention is low melting point glass with a softening temperature of ?40° C. to 300° C., melts at lower temperatures compared to conventional glass, and can safely form the cover without damaging the LED element. Since glass has better moisture shield performance and resistance to light compared to epoxy resins, the cover is formed using glass, and consequently deterioration of the LED element and a phosphor caused by moisture is reduced, deterioration of the cover caused by light is reduced, and changes in color and luminous intensity are restrained.Type: GrantFiled: July 29, 2004Date of Patent: September 4, 2007Assignees: Seiwa Electric Mfg. Co., Ltd.Inventors: Toshinobu Yoko, Masahide Takahashi, Kenji Matsuno
-
Publication number: 20070166824Abstract: The present invention is directed to methods for the expansion of non-terminally differentiated cells (“precursor cells”) using agonists of Notch function, by inhibiting the differentiation of the cells without inhibiting proliferation (mitotic activity) such that an expanded population of non-terminally differentiated cells is obtained. The cells are preferably stem or progenitor cells. These expanded cells can be used in cell replacement therapy to provide desired cell populations and help in the regeneration of diseased and/or injured tissues. The expanded cell populations can also be made recombinant and used for gene therapy, or can be used to supply functions associated with a particular precursor cell or its progeny cell.Type: ApplicationFiled: November 28, 2006Publication date: July 19, 2007Inventors: Spyridon Artavanis-Tsakonas, Mark Fortini, Kenji Matsuno
-
Publication number: 20070092662Abstract: The present invention provides a polarizer comprising a polarizing film, a first transparent protective film and a second transparent protective film, the polarizing film being between the first transparent protective film and the second transparent protective film, wherein the first transparent protective film has a water-vapor permeability of 50 g/m2·24 hours or less at 40° C. under a relative humidity of 90 % and a water content of the polarizer is 2.0% by weight or less.Type: ApplicationFiled: September 5, 2006Publication date: April 26, 2007Inventors: Kenji MATSUNO, Toshiya Inoue
-
Publication number: 20060063770Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: ApplicationFiled: August 8, 2005Publication date: March 23, 2006Applicants: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Anjali Pandey, Robert Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Patent number: 7005086Abstract: A fluorescent substance is obtained by weighing and mixing CaS, Ga2S3, EuS and Ce2S3 in a mole ratio of (1-x):a:x:y (wherein 0.001?x?0.2, 0.0001?y?0.02 and 0.5?a?5) and by sintering the mixture. A light-emitting diode comprises an LED chip 2 and an LED chip sealing portion 5, made of silicone resin and including the fluorescent substance, for enclosing the LED chip 2. Hence, a fluorescent substance that is excited by light having a predetermined wavelength to emit light, a light-emitting diode having excellent luminous efficiency and luminous intensity, and a method for producing the fluorescent substance are attained by the present invention.Type: GrantFiled: November 6, 2003Date of Patent: February 28, 2006Assignee: Seiwa Electric Mfg. Co., Ltd.Inventor: Kenji Matsuno
-
Patent number: 6982266Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: GrantFiled: August 17, 2001Date of Patent: January 3, 2006Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Publication number: 20050288297Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: ApplicationFiled: August 22, 2005Publication date: December 29, 2005Applicants: Millennium pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Anjali Pandey, Robert Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Patent number: 6956039Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: GrantFiled: August 17, 2001Date of Patent: October 18, 2005Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Publication number: 20050158859Abstract: The present invention is directed to methods for the expansion of non-terminally differentiated cells (“precursor cells”) using agonists of Notch function, by inhibiting the differentiation of the cells without inhibiting proliferation (mitotic activity) such that an expanded population of non-terminally differentiated cells is obtained. The cells are preferably stem or progenitor cells. These expanded cells can be used in cell replacement therapy to provide desired cell populations and help in the regeneration of diseased and/or injured tissues. The expanded cell populations can also be made recombinant and used for gene therapy, or can be used to supply functions associated with a particular precursor cell or its progeny cell.Type: ApplicationFiled: December 22, 2003Publication date: July 21, 2005Inventors: Spyridon Artavanis-Tsakonas, Mark Fortini, Kenji Matsuno
-
Publication number: 20050101609Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method ol inhibiling kinascs and tre ating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention prtvides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: ApplicationFiled: August 17, 2001Publication date: May 12, 2005Inventors: Anjali Pandey, Robert Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Publication number: 20050023540Abstract: In an LED (Light Emitting Diode) including a cover covering an LED element, the cover is formed using glass having a composition RnSiO2?n/2. The glass according to the present invention is low melting point glass with a softening temperature of ?40° C. to 300° C., melts at lower temperatures compared to conventional glass, and can safely form the cover without damaging the LED element. Since glass has better moisture shield performance and resistance to light compared to epoxy resins, the cover is formed using glass, and consequently deterioration of the LED element and a phosphor caused by moisture is reduced, deterioration of the cover caused by light is reduced, and changes in color and luminous intensity are restrained.Type: ApplicationFiled: July 29, 2004Publication date: February 3, 2005Inventors: Toshinobu Yoko, Masahide Takahashi, Kenji Matsuno
-
Publication number: 20040259881Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating diseases states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: ApplicationFiled: April 1, 2004Publication date: December 23, 2004Inventors: Anjali Pandey, Robert M Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Publication number: 20040186110Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: ApplicationFiled: March 18, 2004Publication date: September 23, 2004Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Publication number: 20040180925Abstract: A compound represented by general formula (I):Type: ApplicationFiled: November 10, 2003Publication date: September 16, 2004Inventors: Kenji Matsuno, Kimihisa Ueno, Yasuhiro Iwata, Yuichi Matsumoto, Satoshi Nakanishi, Kotaro Tasaki, Hideaki Kusaka, Yuji Nomoto, Akira Ogawa
-
Publication number: 20040176594Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomeruloscierosis.Type: ApplicationFiled: March 18, 2004Publication date: September 9, 2004Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Patent number: 6750218Abstract: 1,3 Diazines according to formula: and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering.Type: GrantFiled: August 26, 2002Date of Patent: June 15, 2004Assignee: Millenniumium Pharmaceuticals, Inc.Inventors: Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shigeki Fujiwara, Shinichi Ide, Eiji Tsukuda, Junko Irie, Shoji Oda
-
Publication number: 20040089846Abstract: A fluorescent substance is obtained by weighing and mixing CaS, Ga2S3, EuS and Ce2S3 in a mole ratio of (1-x):a:x:y (wherein 0.001≦x≦0.2, 0.0001≦y≦0.02 and 0.5≦a≦5) and by sintering the mixture. A light-emitting diode comprises an LED chip 2 and an LED chip sealing portion 5, made of silicone resin and including the fluorescent substance, for enclosing the LED chip 2. Hence, a fluorescent substance that is excited by light having a predetermined wavelength to emit light, a light-emitting diode having excellent luminous efficiency and luminous intensity, and a method for producing the fluorescent substance are attained by the present invention.Type: ApplicationFiled: November 6, 2003Publication date: May 13, 2004Inventor: Kenji Matsuno
-
Publication number: 20040058443Abstract: The present invention is directed to methods for the expansion of non-terminally differentiated cells (“precursor cells”) using agonists of Notch function, by inhibiting the differentiation of the cells without inhibiting proliferation (mitotic activity) such that an expanded population of non-terminally differentiated cells is obtained. The cells are preferably stem or progenitor cells. These expanded cells can be used in cell replacement therapy to provide desired cell populations and help in the regeneration of diseased and/or injured tissues. The expanded cell populations can also be made recombinant and used for gene therapy, or can be used to supply functions associated with a particular precursor cell or its progeny cell.Type: ApplicationFiled: April 18, 2003Publication date: March 25, 2004Applicant: Yale UniversityInventors: Spyridon Artavanis-Tsakonas, Mark Edward Fortini, Kenji Matsuno
-
Publication number: 20030229077Abstract: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: ApplicationFiled: August 26, 2002Publication date: December 11, 2003Inventors: Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shigeki Fujiwara, Shinichi Ide, Eiji Tsukuda, Junko Irie, Shoji Oda